Contact
searchSearch
HMP Global
Login

Bipolar Disorders Topic Center

Conference presenter
News
Olanzapine/Samidorphan Demonstrates Favorable Safety Profile in 4-Year Open-Label Study
11/01/2024
Brionna Mendoza
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination...
11/01/2024
Psych Congress Network
Delusion Themes Stay Consistent Across Psychosis Episodes
News
Delusion Themes Stay Consistent Across Psychosis Episodes, Study Finds
08/20/2024
Jolynn Tumolo
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry. 
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry. 
Delusion content was similar...
08/20/2024
Psych Congress Network
fda
News
FDA Approves Iloperidone for Acute Treatment of Bipolar I Disorder
04/08/2024
Meagan Thistle
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for...
04/08/2024
Psych Congress Network
Patients With First-Episode Psychosis Found to Have Cognitive Impairment Before Medication Use
News
Patients With First-Episode Psychosis Found to Have Cognitive Impairment Before Medication Use
03/26/2024
Evi Arthur
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Patients with first-episode...
03/26/2024
Psych Congress Network
Young Adults Who Self-Harm May Be More at Risk of Psychosis Diagnosis
News
Young Adults Who Self-Harm May Be More at Risk of Psychosis Diagnosis
02/27/2024
Evi Arthur
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
Young adults and teenagers who...
02/27/2024
Psych Congress Network
Death risk increased by how much with a bipolar disorder diagnosis?
Quiz
Death risk increased by how much with a bipolar disorder diagnosis?
02/26/2024
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/26/2024
Psych Congress Network
Bipolar Disorder Increases Mortality Risk More Than Smoking
News
Bipolar Disorder Increases Mortality Risk More Than Smoking
02/05/2024
Jolynn Tumolo
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.  
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.  
A diagnosis of bipolar disorder...
02/05/2024
Psych Congress Network
Brain with puzzle piece missing
News
Vitamin B6 Plus Lithium Helps Ease Mania Symptoms in Patients With Bipolar Disorder
01/03/2024
Jolynn Tumolo
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
Daily vitamin B6 as adjunctive...
01/03/2024
Psych Congress Network
News
Use of Psilocbyin in Bipolar II Treatment Clinical Trial Produces Strong Results
12/12/2023
Tom Valentino
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by...
12/12/2023
Psych Congress Network
bipolar disorder graphic
News
Metformin Helps Prevent Weight Gain in Youth Taking Medication for Bipolar Disorder
11/15/2023
Jolynn Tumolo
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The type 2 diabetes drug...
11/15/2023
Psych Congress Network
News
FDA Approves ABILIFY ASIMTUFII for Schizophrenia and Bipolar Disorder Treatment
04/28/2023
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder. 
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder. 
The FDA approved ABILIFY...
04/28/2023
Psych Congress Network

News

Conference presenter
News
Olanzapine/Samidorphan Demonstrates Favorable Safety Profile in 4-Year Open-Label Study
11/01/2024
Brionna Mendoza
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination...
11/01/2024
Psych Congress Network
Delusion Themes Stay Consistent Across Psychosis Episodes
News
Delusion Themes Stay Consistent Across Psychosis Episodes, Study Finds
08/20/2024
Jolynn Tumolo
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry. 
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry. 
Delusion content was similar...
08/20/2024
Psych Congress Network
fda
News
FDA Approves Iloperidone for Acute Treatment of Bipolar I Disorder
04/08/2024
Meagan Thistle
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for...
04/08/2024
Psych Congress Network
Patients With First-Episode Psychosis Found to Have Cognitive Impairment Before Medication Use
News
Patients With First-Episode Psychosis Found to Have Cognitive Impairment Before Medication Use
03/26/2024
Evi Arthur
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Patients with first-episode...
03/26/2024
Psych Congress Network
Young Adults Who Self-Harm May Be More at Risk of Psychosis Diagnosis
News
Young Adults Who Self-Harm May Be More at Risk of Psychosis Diagnosis
02/27/2024
Evi Arthur
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
Young adults and teenagers who...
02/27/2024
Psych Congress Network
Bipolar Disorder Increases Mortality Risk More Than Smoking
News
Bipolar Disorder Increases Mortality Risk More Than Smoking
02/05/2024
Jolynn Tumolo
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.  
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.  
A diagnosis of bipolar disorder...
02/05/2024
Psych Congress Network
Brain with puzzle piece missing
News
Vitamin B6 Plus Lithium Helps Ease Mania Symptoms in Patients With Bipolar Disorder
01/03/2024
Jolynn Tumolo
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
Daily vitamin B6 as adjunctive...
01/03/2024
Psych Congress Network
News
Use of Psilocbyin in Bipolar II Treatment Clinical Trial Produces Strong Results
12/12/2023
Tom Valentino
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by...
12/12/2023
Psych Congress Network
bipolar disorder graphic
News
Metformin Helps Prevent Weight Gain in Youth Taking Medication for Bipolar Disorder
11/15/2023
Jolynn Tumolo
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The type 2 diabetes drug...
11/15/2023
Psych Congress Network
News
FDA Approves ABILIFY ASIMTUFII for Schizophrenia and Bipolar Disorder Treatment
04/28/2023
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder. 
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder. 
The FDA approved ABILIFY...
04/28/2023
Psych Congress Network
open and spilled bottle of pills
News
Beta-Blockers Ineffective for Treating Psychological Symptoms of Anxiety
04/24/2025
Maria Mantas
A systematic review found no evidence of a beneficial effect from beta-blockers in treating anxiety symptoms in patients with social phobia or panic disorder with or without agoraphobia compared to either placebo or benzodiazepines.
A systematic review found no evidence of a beneficial effect from beta-blockers in treating anxiety symptoms in patients with social phobia or panic disorder with or without agoraphobia compared to either placebo or benzodiazepines.
A systematic review found no...
04/24/2025
Psych Congress Network
tipped over pill bottle with white pills spilling out
News
Fewer Than Half of Medicaid Managed Care Plans Cover All Medications For AUD
04/22/2025
Maria Mantas
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid...
04/22/2025
Psych Congress Network
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
strand of DNA
News
Genetic Liability for Schizophrenia May Affect Traumatic Brain Injury Associations
04/21/2025
Jolynn Tumolo
A genetic liability for schizophrenia and other mental disorders appears to factor into the associations between traumatic brain injury and mental disorder and suicide, according to study findings.
A genetic liability for schizophrenia and other mental disorders appears to factor into the associations between traumatic brain injury and mental disorder and suicide, according to study findings.
A genetic liability for...
04/21/2025
Psych Congress Network
injection for schizophrenia treatment
News
Antipsychotic Sedation Peaks in First 2 Weeks, Emphasizing Importance of Early Monitoring
04/21/2025
Maria Mantas
A meta-analysis of randomized controlled trials (RCTs) of antipsychotic monotherapy for the acute phase of schizophrenia and schizoaffective disorder (SSD) found that sedation onset peaked within the first 2 weeks of treatment initiation.
A meta-analysis of randomized controlled trials (RCTs) of antipsychotic monotherapy for the acute phase of schizophrenia and schizoaffective disorder (SSD) found that sedation onset peaked within the first 2 weeks of treatment initiation.
A meta-analysis of randomized...
04/21/2025
Psych Congress Network
older woman with depression
News
Evidence Lacking for TRD Treatment Effectiveness in Older Adults, Review Finds
04/16/2025
Maria Mantas
A recent systematic review found weak quality evidence to support the effectiveness of several commonly prescribed pharmacological and non-pharmacological interventions for treatment-resistant depression (TRD) in older adults. 
A recent systematic review found weak quality evidence to support the effectiveness of several commonly prescribed pharmacological and non-pharmacological interventions for treatment-resistant depression (TRD) in older adults. 
A recent systematic review found...
04/16/2025
Psych Congress Network
Viloxazine Molecule
News
Viloxazine ER: A Nonstimulant in ADHD Treatment
04/14/2025
Viloxazine ER is a nonstimulant medication for ADHD that has a unique mechanism of action compared to traditional stimulant medications, broadening the therapeutic landscape.
Viloxazine ER is a nonstimulant medication for ADHD that has a unique mechanism of action compared to traditional stimulant medications, broadening the therapeutic landscape.
Viloxazine ER is a nonstimulant...
04/14/2025
Psych Congress Network
an assortment of pills spilled out on a yellow table
News
Inpatient Addiction Consultation Service Promotes MOUD in Patients with OUD
04/14/2025
Jolynn Tumolo
According to randomized clinical trial findings, patients with opioid use disorder (OUD) who received inpatient addiction consultation service were more likely to initiate medication for OUD (MOUD) compared to those who received usual care.
According to randomized clinical trial findings, patients with opioid use disorder (OUD) who received inpatient addiction consultation service were more likely to initiate medication for OUD (MOUD) compared to those who received usual care.
According to randomized clinical...
04/14/2025
Psych Congress Network
Hormonal Contraceptive Pills
News
Post Partum Hormonal Contraception Use Linked with Heightened Depression Risk
04/09/2025
Jolynn Tumolo
The initiation of hormonal contraception post partum was associated with an immediate increase in depression risk in first-time mothers in Denmark, according to a study published in JAMA Network Open.
The initiation of hormonal contraception post partum was associated with an immediate increase in depression risk in first-time mothers in Denmark, according to a study published in JAMA Network Open.
The initiation of hormonal...
04/09/2025
Psych Congress Network
A woman taking a pill
News
New Study Finds Quetiapine More Effective Than Lithium in Reducing Treatment-Resistant Depression Symptoms
04/09/2025
Maria Mantas
Quetiapine may be more clinically effective than lithium as an augmentation option for reducing symptoms of treatment-resistant depression (TRD), a type of major depressive disorder (MDD), according to a recent study.
Quetiapine may be more clinically effective than lithium as an augmentation option for reducing symptoms of treatment-resistant depression (TRD), a type of major depressive disorder (MDD), according to a recent study.
Quetiapine may be more...
04/09/2025
Psych Congress Network

Quizzes

Death risk increased by how much with a bipolar disorder diagnosis?
Quiz
Death risk increased by how much with a bipolar disorder diagnosis?
02/26/2024
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/26/2024
Psych Congress Network
polygenic risk scores
Quiz
Is there an association between hospitalization frequency and polygenic risk score?
10/06/2022
Take the quiz to test your clinical knowledge!
Take the quiz to test your clinical knowledge!
Take the quiz to test your...
10/06/2022
Psych Congress Network
COVID-19 risk.
Quiz
Antipsychotic Use and COVID-19 Risk in Patients with BD and SMI
06/15/2022
How does antipsychotic use affect COVID-19 risk? Take the quiz now to test your knowledge!
How does antipsychotic use affect COVID-19 risk? Take the quiz now to test your knowledge!
How does antipsychotic use...
06/15/2022
Psych Congress Network
Quiz
Challenges for Patients With Bipolar Disorder
01/11/2022
According to a recent survey, which of the following concerns did patients with bipolar-I disorder report?
According to a recent survey, which of the following concerns did patients with bipolar-I disorder report?
According to a recent survey,...
01/11/2022
Psych Congress Network
Expert Insights Quiz
Expert Insights Quiz
Effective Strategies to Introduce LAIs to Patients In-Person and Via Telemedicine
04/21/2025
Craig Chepke, MD, DFAPA
Which of the following strategies did Scientific Director for the Psych Congress event portfolio, Dr Craig Chepke, highlight as effective when introducing LAIs to patients with schizophrenia, including those in telemedicine settings?
Which of the following strategies did Scientific Director for the Psych Congress event portfolio, Dr Craig Chepke, highlight as effective when introducing LAIs to patients with schizophrenia, including those in telemedicine settings?
Which of the following...
04/21/2025
Psych Congress Network
a dialogue bubble with the word "quiz"
Quiz
How do inpatient addiction consultation services impact MOUD initiation?
04/21/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
04/21/2025
Psych Congress Network
stacked blocks that spell out the word "quiz"
Quiz
Initial Treatment Approach for Adults in Acute Phase MDD in Ambulatory Care
04/17/2025
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial...
04/17/2025
Psych Congress Network
a sticky note that reads "take the quiz" stuck to a computer keyboard
Quiz
How does menopausal hormone therapy impact outomes in midlife women with schizophrenia?
04/11/2025
According to a 2024 study, what impact did MHT use have on the risk of psychosis relapse in women between ages 40 and 55?
According to a 2024 study, what impact did MHT use have on the risk of psychosis relapse in women between ages 40 and 55?
According to a 2024 study, what...
04/11/2025
Psych Congress Network
an illustrated laptop screen displaying a quiz
Quiz
By What Percentage Did US Drug Overdose Deaths Decline in 2024?
04/10/2025
According to provisional data from the Center for Disease Control and Prevention (CDC), by what percentage did US drug overdose deaths decrease in the 12 months ending in September 2024 compared to the previous year?
According to provisional data from the Center for Disease Control and Prevention (CDC), by what percentage did US drug overdose deaths decrease in the 12 months ending in September 2024 compared to the previous year?
According to provisional data...
04/10/2025
Psych Congress Network
Dr Steven Chan
Expert Insights Quiz
Choosing the Right Digital Therapeutic for MDD Treatment
03/18/2025
Steven Chan, MD, MBA; Meagan Thistle
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress...
03/18/2025
Psych Congress Network
Did OUD diagnoses increase or decrease in VHA patients?
Quiz
Did OUD diagnoses increase or decrease in VHA patients?
02/25/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/25/2025
Psych Congress Network
Charles Raison headshot
Expert Insights Quiz
First-Line Treatment Options for Insomnia
02/21/2025
Charles L. Raison, MD
True or False: According to Psych Congress Steering Committee Member, Charles Raison, MD, the first-line treatment for primary insomnia is medication, including benzodiazepines.
True or False: According to Psych Congress Steering Committee Member, Charles Raison, MD, the first-line treatment for primary insomnia is medication, including benzodiazepines.
True or False: According to...
02/21/2025
Psych Congress Network
Quiz
Quiz
Cariprazine FDA-Approved Indications
02/21/2025
Meagan Thistle
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as...
02/21/2025
Psych Congress Network
How many US Psychiatric Hospitals Provided Medications for OUD?
Quiz
How many US psychiatric hospitals provided medications for OUD?
02/06/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/06/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use